Acumen Pharmaceuticals, Inc. (ABOS) Stock Score, Valuation & Financial Research

Acumen Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ABOS

Acumen Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.22. These figures are a research snapshot, not a buy or sell recommendation.

What Acumen Pharmaceuticals, Inc. does

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and entering into strategic research and development collaborations to fund the clinical advancement of its proprietary therapeutic candidates for Alzheimer's disease.

Products and services

  • The company is developing sabirnetug (ACU193), a humanized monoclonal antibody designed to target toxic soluble amyloid-beta oligomers for the treatment of Alzheimer's disease.

Brands and product families

  • sabirnetug (ACU193) — Lead therapeutic candidate currently in Phase 2 clinical development. Source

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • JCR Pharmaceuticals Co. Ltd. — A collaboration, option, and license agreement to develop an Aβ oligomer-targeted Enhanced Brain Delivery (EBD) therapy for Alzheimer's disease using JCR's J-Brain Cargo technology. Source

Competitors and product-market comparisons

  • Biogen Inc. — Develops and markets therapies for Alzheimer's disease, including monoclonal antibodies targeting amyloid-beta. Source
  • Eli Lilly and Company — Develops and markets therapies for Alzheimer's disease, including monoclonal antibodies targeting amyloid-beta. Source
  • Eisai Co., Ltd. — Develops and markets therapies for Alzheimer's disease, including monoclonal antibodies targeting amyloid-beta. Source

Business strengths to evaluate

  • Proprietary focus on toxic soluble amyloid-beta oligomers (AβOs) as a therapeutic target. Source
  • Strategic partnership with JCR Pharmaceuticals to enhance brain delivery of therapies. Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses for the foreseeable future. Source
  • Significant dependence on the success of a single lead product candidate, sabirnetug. Source
  • Risks associated with clinical trial outcomes, regulatory approval processes, and reliance on third-party manufacturers. Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ABOS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.22
Market capitalization:
160.35M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -105.04M
Free cash flow:
USD -115.63M
Cash:
USD 59.44M
Total debt:
USD 31.57M
EPS:
USD -1.64

What stands out

  • Free cash flow is USD -115.63M, negative for the stored period.
  • The balance sheet shows USD 59.44M of cash versus USD 31.57M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 27.87M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ABOS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ABOS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ABOS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ABOS to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ABOS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ABOS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.